Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Roivant Sciences Ltd. - Common Shares
(NQ:
ROIV
)
35.13
+0.10 (+0.29%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Roivant Sciences Ltd. - Common Shares
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
↗
June 02, 2023
Big Pharma is facing a patent cliff that could siphon off billions in revenue.
Via
Investor's Business Daily
Marching Towards FDA Approval: Dermavant's Vtama Cream Excels in Phase 3 Trial, Eyes 2024 Submission
↗
May 16, 2023
Dermavant Sciences, a Roivant Sciences (NASDAQ: ROIV) company, announced results from ADORING 1 Phase 3 trial of topical Vtama (tapinarof) cream, 1% in adults and pediatric subjects down to 2 years old...
Via
Benzinga
Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old
May 16, 2023
From
Roivant Sciences
Via
GlobeNewswire
Why Shares of Roivant Sciences Jumped This Week
↗
April 20, 2023
The company's stock benefited from another company's buyout.
Via
The Motley Fool
Analyst Expectations for Roivant Sciences's Future
↗
March 16, 2023
Via
Benzinga
Roivant Sciences Highlights Topline Data From Atopic Dermatitis Drug In Patients As Young As 2 Years
↗
March 15, 2023
Via
Benzinga
Why Did Pfizer Offload This Potential Mega-Blockbuster Drug?
↗
April 23, 2023
Pfizer's decision to offload a potential mega-blockbuster may seem counterintuitive, but the drugmaker appears to have solid reasons for doing so.
Via
The Motley Fool
These 2 Growth Stocks Might Be Incredibly Undervalued Right Now
↗
April 20, 2023
These two biopharma stocks could be poised for a major growth spurt.
Via
The Motley Fool
EXCLUSIVE: Joe Biden Tops 2024 Election Betting Odds, How Negative Headlines And Indictment Move Trump Ahead Of DeSantis
↗
April 17, 2023
While the 2024 U.S. presidential election may seem a long way off, polls to see who is favored by voters and betting odds for the next White House occupant have ramped up.
Via
Benzinga
These 3 Nasdaq Stocks Are on Fire Today: Here's Why
↗
April 17, 2023
A high-dollar buyout is lighting a fire underneath these three Nasdaq stocks today.
Via
The Motley Fool
Merck Nabs Prometheus Bio For $10.8 Billion As Keytruda Patent Expirations Loom
↗
April 17, 2023
Merck is branching into immune-mediated diseases with this takeover.
Via
Investor's Business Daily
Prometheus Biosciences, XPeng And Other Big Stocks Moving Higher In Monday's Pre-Market Session
↗
April 17, 2023
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 70.1% to $193.93...
Via
Benzinga
Expert Ratings for Roivant Sciences
↗
February 13, 2023
Via
Benzinga
Roivant Sciences's Earnings Outlook
↗
February 10, 2023
Via
Benzinga
Lokavant Hires Experienced Leaders to Accelerate Growth Trajectory
April 04, 2023
From
Lokavant
Via
Business Wire
Lokavant Emerges from Roivant Sciences with Multiple Industry Partnerships to Accelerate Impact on Clinical Research
April 04, 2023
From
Lokavant
Via
Business Wire
7 Biotech Stocks to Buy for Breakthrough Treatments and Cures
↗
March 29, 2023
For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine.
Via
InvestorPlace
Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients
March 28, 2023
From
Covant Therapeutics
Via
GlobeNewswire
Why Citi Trends Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
March 21, 2023
Gainers U.S. Xpress Enterprises, Inc. (NYSE: USX) shares surged 298% to $5.97 after Knight-Swift Transportation agreed to acquire the company for $6.15 per share.
Via
Benzinga
Why Shares of Roivant Sciences Were Down Tuesday
↗
March 21, 2023
After a run-up last week prompted by positive clinical trial results, the stock has given back its recent gains.
Via
The Motley Fool
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
↗
March 15, 2023
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.
Via
InvestorPlace
Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
March 15, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis
March 14, 2023
From
Roivant Sciences
Via
GlobeNewswire
Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader Programs
March 14, 2023
PVTX-321 and PVTX-405 Achieve Development Candidate Nomination
From
Roivant Sciences
Via
GlobeNewswire
Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement
March 07, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant Sciences Announces Change to its Board of Directors
February 21, 2023
From
Roivant Sciences
Via
GlobeNewswire
Immunovant Could Potentially Be An M&A Target, Writes Analyst
↗
February 15, 2023
Via
Benzinga
Mixed Signals On Valentine's Day: How Stocks Are Reacting To January Inflation Data
↗
February 14, 2023
Inflation cooled slightly in January, but saw increases in some areas due to the impact of surging food, energy and shelter prices on consumers, the U.S Labor Department said Tuesday.
Via
Benzinga
Roivant Sciences Reports Financial Results for the Third Quarter Ended December 31, 2022 and Provides Business Update
February 13, 2023
From
Roivant Sciences
Via
GlobeNewswire
Earnings Scheduled For February 13, 2023
↗
February 13, 2023
Companies Reporting Before The Bell • EuroDry (NASDAQ:EDRY) is expected to report quarterly earnings at $2.68 per share on revenue of $21.20 million.
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
